Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04126746 · ClinicalTrials.gov registry record
Clinical Trials in Organ Transplantation Extension Study
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 501
- Enrollment target
NCT04126746: Completed study, sponsored by Duke University.
NCT04126746 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 501 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04126746 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 501 participants
- Enrollment target
Study Summary
The purpose of the study is to continue to follow subjects who were enrolled in the CTOT-20 CLAD Phenotypes study. Subjects will provide clinical data and complete quality of life questionnaires that will be used to determine the clinical factors associated with the development of Chronic Lung Allograft Dysfunction (CLAD) after lung transplant.
Primary Outcome
Time from lung transplant to the development of CLAD (Restrictive Chronic Lung Allograft Dysfunction (RCLAD) or Bronchiolitis Obliterans Syndrome (BOS) as measured by a change in pulmonary function and Physician Adjudication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2024-08-26 |
What the finished NCT04126746 record still lists
NCT04126746 is an observational study that tracks outcomes without assigning an intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04126746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04126746 about?
NCT04126746 is a clinical study titled "Clinical Trials in Organ Transplantation Extension Study". The purpose of the study is to continue to follow subjects who were enrolled in the CTOT-20 CLAD Phenotypes study. Subjects will provide clinical data and complete quality of life questionnaires that will be used to determine the clinical factors associated with the development of Chronic Lung Allog...
What is the current status of trial NCT04126746?
This trial is currently completed. The enrollment target is 501 participants. The study started on 2019-12-17. Estimated completion is 2024-08-26.
Who is sponsoring clinical trial NCT04126746?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI